Aminazine pills 50mg №10

Indications

Chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes), alcoholic psychosis, manic arousal in manic-depressive psychosis, mental disorders in case of epilepsy, manic agitation in a manic-depressive psychosis, mental disorders in case of epilepsy, manic arousal in a manic-depressive psychosis, mental disorders in case of epilepsy, manic arousal in a manic-depressive psychosis, mental disorders in case of epilepsy, manic arousal in a manic-depressive psychosis; depressive psychosis, as well as other diseases accompanied by agitation, tension. Neurotic diseases accompanied by increased muscle tone. Persistent pain, incl. causalgia (in combination with analgesics), persistent sleep disorders (in combination with hypnotics and tranquilizers). Meniere's disease, pregnant vomiting, treatment and prevention of vomiting in the treatment of antitumor agents and during radiation therapy. Itchy dermatosis. As part of "lytic mixtures" in anesthesiology.

Dosing regimen

Installed individually. When ingested for adults, a single dose is 10-100 mg, daily dose - 25-600 mg; for children aged 1-5 years - 500 mcg / kg every 4-6 hours, for children older than 5 years, you can apply 1 / 3-1 / 2 adult doses.

With the / m or / in the introduction for adults, the initial dose - 25-50 mg. With the / m or / in the introduction of children older than 1 year, a single dose of 250-500 mg / kg.

The frequency of oral or parenteral administration depends on the evidence and the clinical situation.

Maximum single dose: for adults, by ingestion - 300 mg, with a / m injection - 150 mg, with a / in the introduction - 100 mg.

Maximum daily doses: for adults, by ingestion - 1.5 g, with a / m injection - 1 g, with a / in the introduction - 250 mg; for children under 5 years of age (body weight up to 23 kg) when taken orally, intramuscularly or intravenously, 40 mg, for children over 5 years old (body weight more than 23 kg) when taken orally, into / m or / in the introduction of 75 mg.

Adverse Effects

From the side of the central nervous system: possible akathisia, blurred vision; rarely - dystonic extrapyramidal reactions, parkinson syndrome, tardive dyskinesia, disturbances of thermoregulation, MNS; in isolated cases - seizures.

Cardiovascular: possible arterial hypotension (especially with a / in the introduction), tachycardia.

Gastrointestinal: possible dyspeptic phenomena (by ingestion); rarely - cholestatic jaundice.

Hemic and lymphatic: rarely - leukopenia, agranulocytosis.

Urogenital: rarely - difficulty urinating.

On the part of the endocrine system: menstrual disorders, impotence, gynecomastia, weight gain.

Allergic reactions: possible skin rash, itching; rarely - exfoliative dermatitis, erythema multiforme.

Dermatologic: rarely - skin pigmentation, photosensitivity.

Special senses: with prolonged use in high doses, chlorpromazine may be deposited in the anterior structures of the eye (cornea and lens), which can accelerate the processes of normal aging of the lens.

Contraindications

Violations of the liver, kidneys, blood-forming organs, progressive systemic diseases of the brain and spinal cord, myxedema, severe cardiovascular diseases, thromboembolic disease; late stage bronchiectasis; angle-closure glaucoma; urinary retention associated with prostatic hyperplasia; pronounced depression of the central nervous system, coma, brain injury.

Pregnanacy and breastfeeding

If necessary, the use of chlorpromazine during pregnancy should limit the treatment time, and at the end of pregnancy, if possible, reduce the dose. It should be borne in mind that chlorpromazine prolongs labor.

If necessary, use during lactation breastfeeding should be discontinued.

Chlorpromazine and its metabolites penetrate the placental barrier, excreted in breast milk.

Clinical studies have shown that chlorpromazine may have a teratogenic effect. When using chlorpromazine in high doses during pregnancy in newborns, in some cases, digestive disorders associated with atropin-like effect, extrapyramidal syndrome were noted.

Application for violations of the liver

Contraindicated in violations of the liver.

Application for violations of kidney function

Contraindicated in violations of the kidneys.

Use in children

Use in children is possible according to the dosing regimen.

In children, especially with acute diseases, the use of phenothiazines is more likely to develop extrapyramidal symptoms.

Use in elderly patients

Phenothiazines should be used with caution in elderly patients (increased risk of excessive sedative and hypotensive action).

Special notes

With particular caution, phenothiazines are used in patients with pathological changes in the blood picture, in disorders of liver function, alcohol intoxication, Reye's syndrome, as well as in breast cancer, cardiovascular diseases, susceptibility to the development of glaucoma, Parkinson's disease, gastric ulcer and duodenal ulcer., urinary retention, chronic diseases of the respiratory system (especially in children), epileptic seizures.

Phenothiazines should be used with caution in elderly patients (increased risk of excessive sedative and hypotensive action), in exhausted and weakened patients.

In the event of hyperthermia, which is one of the symptoms of ZNS, chlorpromazine should be immediately canceled.

In children, especially with acute diseases, the use of phenothiazines is more likely to develop extrapyramidal symptoms.

During the period of treatment to prevent the use of alcohol.

Influence on ability to drive motor transport and control mechanisms

It should be used with caution in patients engaged in potentially hazardous activities that require a high rate of psychomotor reactions.

Drug interactions

With the simultaneous use of drugs that have a depressant effect on the central nervous system, ethanol, ethanol-containing drugs may increase the inhibitory effect on the central nervous system, as well as respiratory depression.

With the simultaneous use of tricyclic antidepressants, maprotiline, MAO inhibitors may increase the risk of developing NNS.

At simultaneous use with anticonvulsants it is possible to decrease the threshold of convulsive readiness; with agents for the treatment of hyperthyroidism - an increased risk of agranulocytosis; with drugs that cause extrapyramidal reactions - an increase in the frequency and severity of extrapyramidal disorders is possible; with drugs that cause arterial hypotension - perhaps an additive effect on blood pressure, which leads to severe arterial hypotension, increased orthostatic hypotension.

When used simultaneously with amphetamines, antagonistic interaction is possible; with anticholinergics - increased anticholinergic action; with anticholinesterase agents - muscle weakness, worsening of the course of myasthenia.

With simultaneous use with antacids containing aluminum and Magnesium hydroxide, the concentration of chlorpromazine in the blood plasma decreases due to a violation of its absorption from the gastrointestinal tract.

With simultaneous use of barbiturates increase the metabolism of chlorpromazine, inducing microsomal liver enzymes and thereby reducing its concentration in the blood plasma.

With the simultaneous use of hormonal contraceptives for oral administration described a case of increasing the concentration of chlorpromazine in the blood plasma.

With simultaneous use with epinephrine, a "perversion" of the pressor action of epinephrine is possible, as a result, only β-adrenoreceptors are stimulated and severe hypotension and tachycardia occur.

With simultaneous use with Amitriptyline increases the risk of tardive dyskinesia. Cases of the development of paralytic ileus are described.

With simultaneous use, chlorpromazine may reduce or even completely inhibit the antihypertensive effect of guanethidine, although some patients may show the hypotensive effect of chlorpromazine.

With simultaneous use with diazoxide, severe hyperglycemia is possible; with doxepin - potentiation of hyperpyrexia; with zolpidem - significantly increased sedative effect; with zopiclone - may increase the sedative effect; with imipramine - the concentration of imipramine in the blood plasma increases.

With simultaneous use of chlorpromazine inhibits the effects of levodopa due to the blockade of dopamine receptors in the central nervous system. Extrapyramidal symptoms may increase.

With simultaneous use of lithium carbonate, pronounced extrapyramidal symptoms, neurotoxic effects are possible; with morphine - the development of myoclonus is possible.

With simultaneous use of nortriptyline in patients with schizophrenia, a worsening of the clinical condition is possible, despite an elevated level of chlorpromazine in the blood plasma. Cases of the development of paralytic ileus are described.

With simultaneous use with piperazine, a case of seizures has been described; with propranolol - an increase in plasma concentrations of propranolol and chlorpromazine; with trazodone - hypotension is possible; with trihexyphenidyl - there are reports of the development of paralytic ileus; with trifluoperazine - cases of severe hyperpyrexia are described; with phenytoin - it is possible to increase or decrease the concentration of phenytoin in the blood plasma.

With simultaneous use with Fluoxetine increases the risk of extrapyramidal symptoms; with chloroquine, sulfadoxine / pyrimethamine, the concentration of chlorpromazine in the blood plasma increases with the risk of the development of the toxic effect of chlorpromazine.

With simultaneous use of cisapride, the QT interval on the ECG is additively extended.

With simultaneous use with cimetidine may decrease the concentration of chlorpromazine in the blood plasma. There is also evidence to suggest an increase in plasma concentration of chlorpromazine.

With simultaneous use of ephedrine may weaken the vasoconstrictor effect of ephedrine.